Klotho Neurosciences, Inc. (KLTO) Research

Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-202, aimed at treating or averting amyotrophic lateral sclerosis. Formerly known as Anew Medical, Inc., the company underwent a name change to Klotho Neurosciences, Inc. in September 2024. The firm's main office is situated in Omaha, Nebraska.

Market snapshot

Symbol
KLTO
Price
$0.38
Day change
-7.10%
Market cap
$21.0M
P/E ratio
-1.99x
52-week range
0.114-3.91
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Cadrenal Therapeutics, Inc. Common Stock (CVKD)
  • iBio, Inc. (IBIO)
  • MetaVia Inc. (MTVA)
  • Minerva Neurosciences, Inc. (NERV)
  • NeuroSense Therapeutics Ltd. (NRSN)
  • NeurAxis, Inc. (NRXS)
  • Rallybio Corporation (RLYB)
  • Sonnet BioTherapeutics Holdings, Inc. (SONN)

Recent insider activity

  • LeBlanc Jeff — A-Award (2500000 shares) on 2026-03-04
  • El-Dada Riad Hussein — A-Award (350000 shares) on 2026-03-04
  • ZENTMAN SAMUEL M — A-Award (350000 shares) on 2026-03-04
  • Hirschman Shalom — A-Award (350000 shares) on 2026-03-04
  • McGarity Jon — A-Award (350000 shares) on 2026-03-04

Open Klotho Neurosciences, Inc. (KLTO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.